Biodexa Pharmaceuticals (BDRX) Notes Payables (2019 - 2025)

Biodexa Pharmaceuticals (BDRX) has 7 years of Notes Payables data on file, last reported at $3.9 million in Q4 2025.

• For the quarter ending Q4 2025, Notes Payables rose 688.77% year-over-year to $3.9 million; the trailing twelve-month figure through Dec 2025 stood at $3.9 million (up 688.77% YoY), and the FY2025 full-year result was $3.8 million, up 681.86% from the prior year.
• Notes Payables climbed to $3.9 million in Q4 2025, from $56029.9 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $5.2 million in Q4 2023 to a low of $56029.9 in Q2 2025.
• A 5-year average of $1.5 million and a median of $618515.5 in 2021 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables jumped 5078.78% in 2023 and plunged 96.17% in 2025, its largest moves.
• Tracing BDRX's Notes Payables over 5 years: stood at $745449.9 in 2021, then slumped by 86.63% to $99698.9 in 2022, then jumped by 5078.78% to $5.2 million in 2023, then slumped by 90.48% to $491581.2 in 2024, then surged by 688.77% to $3.9 million in 2025.
• Business Quant data shows BDRX's Notes Payables at $3.9 million in Q4 2025, $56029.9 in Q2 2025, and $491581.2 in Q4 2024.